Newmanbrain which is part of the PCUMH is specialized in the development of software and hardware for biomedical use, mainly in the areas of neurosciences and biomedicine.
The spin-off of the UMH Scientific Park Newmanbrain has been chosen as a finalist in the contest “Innova Proyecto del IV Certamen Premios Innova eVIA”. The company is specialized in the development of software and hardware for biomedical use, mainly in the areas of neuroscience and biomedicine. After the first choice of finalists, a jury of experts will conduct a second evaluation in which the winners of each category will be selected. The Innova eVIA Awards seek to recognize the effort in scientific and scientific excellence and innovative solutions and developed services in the field of applied technologies to Health and Active Independent Living.
As its CEO , Pablo Belmonte, points out, this recognition is an important boost for the company: “Being among the best in the area of applied technology to neurosciences and recognizing the effort made, entails a great satisfaction for our team. ” In addition, as part of its award, Newmanbrain will be able to publicize its project in the exhibition organized by the event. This will take place during the day of the awards ceremony which will be held on Thursday, March 22 in Madrid.
During this event, the spin-off part of the Scientific Park of the UMH will present to the attendees some of the innovative technologies that they have developed for biomedical use. “We will show how our device works for the analysis of brain activity. A portable system that uses near infrared technology (fNIR) to measure and record brain functions,” says Belmonte. Furthermore, the company will show how this device helps to relate the response to certain stimuli (affective, cognitive, etc.) and alsod it relationship with the changes in cerebral blood flow that occurs during mental activity.
Newmanbrain is driven by the former director of the Institute of Neurosciences (IN), a mixed center between the UMH and the Higher Council for Scientific Research (CSIC), and professor emeritus of the UMH, Carlos Belmonte, by the worker of the Neurosciences Institute Alejandro Méndez, by the director of the Department of Physiology of the UMH, Joaquín Ibáñez, and by Pablo Belmonte. Currently, the company is focused on improving the software and hardware of its device to make it a product of high demand for professionals in Psychology and other potential buyers. Moreover, the company is developing new equipment for the assessment of various biological functions, using fNIR technology.